1

S SENATE BILL 899

Short Title:	Diagnostic Imaging Parity.	(Public)
Sponsors:	Senators Batch, Mayfield, and Chaudhuri (Primary Sponsors).	
Referred to:	Rules and Operations of the Senate	

## May 6, 2024

			May 6, 2024		
1			A BILL TO BE ENTITLED		
2			VIDING HEALTH COVERAGE PARITY FOR BREAST CANCER		
3			C IMAGING, MAKING TECHNICAL AND CONFORMING CHANGES TO		
4			RAL STATUTES RELATED TO BREAST CANCER SCREENING,		
5			MAMMOGRAPHIC BREAST DENSITY PATIENT NOTIFICATION		
6	_		ENTS, AND APPROPRIATING FUNDS TO THE DEPARTMENT OF		
7			ND HUMAN SERVICES FOR THE PURPOSES OF EDUCATING		
8	HEALTHCARE PROVIDERS ABOUT THE CHANGES TO HEALTH INSURANCE				
9			OF BREAST CANCER SCREENING AND DIAGNOSIS AND THE		
10	UPDAT				
11			ON REQUIREMENTS.		
12			mbly of North Carolina enacts:		
13			<b>ION 1.(a)</b> Subsections (a1), (b), and (c) of G.S. 58-51-57 are repealed.		
14			<b>ION 1.(b)</b> G.S. 58-51-57 is recodified as G.S. 58-3-271.		
15		SECT	ION 2.(a) G.S. 58-3-271, as enacted by Section 1(a) of this act, reads as		
16	rewritten:				
17			verage for mammograms screening for, and diagnosis of, breast cancer		
18			ervical <del>cancer screening.</del> cancer.		
19	, ,		llowing definitions apply in this section:		
20		<u>(1)</u>	Breast magnetic resonance imaging. – A diagnostic tool that uses a powerful		
21			magnetic field, radio waves, and a computer to produce detailed pictures of		
22			the structures within the breast.		
23		<u>(2)</u>	Breast ultrasound. – A noninvasive diagnostic tool that uses high-frequency		
24		<b>(0)</b>	sound waves to produce detailed images of the breast.		
25		<u>(3)</u>	<u>Cost-sharing requirement. – A deductible, coinsurance, copayment, and any</u>		
26			maximum limitation on the application of a deductible, coinsurance,		
27			copayment, or similar out-of-pocket expense.		
28		<u>(4)</u>	Diagnostic examination for breast cancer. – An examination for breast cancer		
29			that is determined by the healthcare provider treating the patient to be		
30			medically necessary and appropriate and that may include breast magnetic		
31			resonance imaging, breast ultrasound, and diagnostic low-dose		
32			mammography to evaluate the abnormality in the breast that meets one of the		
33			following criteria:		



Insurer. – As defined in G.S. 58-3-167.

Is detected by another means of examination.

34

35

36

<u>a.</u>

**(5)** 

Is seen or suspected from a screening examination for breast cancer.

- Low-dose mammography. – A radiologic procedure for the early detection of (6) breast cancer using equipment dedicated specifically for mammography, including a physician's interpretation of the results of the procedure. Screening examination for breast cancer. – Low-dose mammography, or an <u>(7)</u> equivalent procedure, that is used to determine if there is abnormality in the Screening of early detection of cervical cancer. – Examinations and laboratory (8)
  - (8) Screening of early detection of cervical cancer. Examinations and laboratory tests used to detect cervical cancer, including conventional PAP smear screening, liquid-based cytology, and human papilloma virus (HPV) detection methods for women with equivocal findings on cervical cytologic analysis that are subject to the approval of and have been approved by the United States Food and Drug Administration. examination, the laboratory fee, and the physician's interpretation of the laboratory results
  - (9) Supplemental examination for breast cancer. An examination for breast cancer that is determined by the healthcare provider treating the patient to be medically necessary and appropriate and that may include breast magnetic resonance imaging or breast ultrasound to screen for cancer if the patient meets either of the following criteria:
    - a. The patient is at increased risk for breast cancer based on the patient's personal medical history or family medical history of breast cancer.
    - b. The patient has heterogeneously or extremely dense breast tissue as defined by the Breast Imaging Reporting and Data System established by the American College of Radiology.
  - (b) Every policy or contract of accident or health insurance, and every preferred provider benefit plan under G.S. 58-50-56, that is issued, renewed, or amended on or after January 1, 1992, heath benefit plan offered by an insurer in this State shall provide coverage for examinations and laboratory tests tests, including the laboratory fee and the interpretation of the laboratory results, for the screening for the early detection of cervical cancer and for low-dose screening mammography. The same deductibles, coinsurance, and other limitations as apply to similar services covered under the policy, contract, or plan shall apply to coverage for examinations and laboratory tests for the screening for the early detection of cervical cancer and low-dose screening mammography.
  - (c) Every health benefit plan offered by an insurer in this State that provides benefits for a diagnostic or supplemental examination for breast cancer shall ensure that the cost-sharing requirements applicable to a diagnostic or supplemental examination for breast cancer are no less favorable than the cost-sharing requirements applicable to low-dose screening mammography for breast cancer.
  - (d) Reimbursement for a mammogram <u>authorized required</u> under this section shall be made only if the facility in which the mammogram was performed meets mammography accreditation standards established by the North Carolina Medical Care Commission.
  - (e) Coverage for the screening for the early detection of cervical cancer shall be in accordance with the most recently published American Cancer Society guidelines or guidelines adopted by the North Carolina Advisory Committee on Cancer Coordination and Control. Coverage shall include the examination, the laboratory fee, and the physician's interpretation of the laboratory results. Reimbursements for laboratory fees required under this section shall be made only if the laboratory meets accreditation standards adopted by the North Carolina Medical Care Commission.
  - (f) Coverage for screening examinations for breast cancer and early detection of cervical cancer required under this section shall, at a minimum, be provided in a manner that adheres to the most recent United States Preventative Task Force A, B, and C recommendations."

**SECTION 2.(b)** G.S. 58-65-92 is repealed.

Page 2

1 2 **SECTION 2.(c)** G.S. 58-67-76 is repealed.

**SECTION 3.(a)** G.S. 135-48.51 reads as rewritten:

3 4

## "§ 135-48.51. Coverage and operational mandates related to Chapter 58 of the General Statutes.

5 6 The following provisions of Chapter 58 of the General Statutes apply to the State Health Plan:

7

G.S. 58-3-271, Coverage of screening for, and diagnosis of, breast and (9a) cervical cancer.

8 9 10

11

12

**SECTION 3.(b)** Effective July 1, 2024, there is appropriated from the General Fund to the Department of State Treasurer the sum of nine hundred thousand dollars (\$900,000) in recurring funds for the 2024-2025 fiscal year to ensure compliance with subsection (a) of this section by the North Carolina State Health Plan for Teachers and State Employees.

13 14

**SECTION 4.** G.S. 130A-215.5(a) reads as rewritten:

All health care facilities that perform mammography examinations shall include in "(a) the summary of the mammography report, required by federal law to be provided to a patient, information that identifies the patient's individual breast density classification based on the Breast Imaging Reporting and Data System established by the American College of Radiology. If the facility determines that a patient does not have heterogeneously or extremely dense breasts, the summary of the mammography report shall include the following notice:

20

"Breast tissue can be either dense or not dense. Your mammogram indicates that you do NOT have dense breast tissue. The presence of dense tissue makes it more difficult to detect abnormalities in the breast and increases the risk of breast cancer. We are providing this information to raise your awareness of this important factor and to encourage you to talk to your healthcare provider about breast density, risks for breast cancer, and your individual risk factors."

26 27

28

29

30

31

32

33

34

35

36

37

25

If the facility determines that a patient has heterogeneously or extremely dense breasts, the summary of the mammography report shall include the following notice:

"Breast tissue can be either dense or not dense. Your mammogram indicates that you may have dense breast tissue. Dense breast tissue is relatively common and is found in more than forty percent (40%) of women. The presence of dense tissue may make makes it more difficult to detect abnormalities in the breast and may be associated with an increased increases the risk of breast cancer. You might benefit from supplementary screening, which may include contrast-enhanced mammography (also known as CEM) or magnetic resonance imaging of the breast (also known as Breast MRI), or both, depending on your individual risk factors. We are providing this information to raise your awareness of this important factor and to encourage you to talk with your physician healthcare provider about this and other breast cancer risk factors. Together, you can decide which screening options are right for you. A report of your results was sent to your physician.healthcare provider.""

**SECTION 5.** Effective July 1, 2024, there is appropriated from the General Fund to the Department of Health and Human Services, the sum of one hundred thousand dollars (\$100,000) in nonrecurring funds for the 2024-2025 fiscal year to be used to educate healthcare providers about the changes to health insurance coverage of breast cancer screening and diagnosis and the updates to the mammographic breast density patient notification requirements contained in this act. DHHS shall ensure that, as part of this educational campaign, relevant information is provided to any North Carolina-based organization that includes obstetric and gynecological practitioners as part of its membership.

46 47

48

44

45

**SECTION 6.** Except as otherwise provided, this act becomes effective October 1, 2023, and applies to insurance contracts issued, renewed, or amended on or after that date.